Keith Cooper

Dr. Keith Cooper

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2013 in Journal of Hospital Infection
Verified
Journal Article
Closed access
PDF file
KCKeith Cooper
Keith Cooper
GFG. Frampton
G. Frampton
PHP. Harris
P. Harris
JJJ. Jones
J. Jones
TCT. Cooper
T. Cooper
BCB.H. Cuthbertson
B.H. Cuthbertson

15 November 2006 in Health Care Management Science
Verified
Journal Article
Closed access
PDF file
KCKeith Cooper
Keith Cooper
Sally BrailsfordSally Brailsford
Sally Brailsford
RDR. Davies
R. Davies
JRJ. Raftery
J. Raftery

1 September 2008 in Journal of the Operational Research Society
Verified
Journal Article
Closed access
KCKeith Cooper
Keith Cooper
RDR Davies
R Davies
JRJ Raftery
J Raftery
PRP Roderick
P Roderick
A discrete event simulation model of the patient pathways in the treatment of coronary heart disease (CHD) was used to quantify the health gains and costs associated with increasing secondary prevention drugs prescription for patients with CHD based on the level recommended in the National Service Framework for the UK. A Gompertz distribution was sampled for time to failure (death or non-fatal heart attack). The time to failure was modified in relation to the reduced risk of failure for those on the relevant drugs. The results from the model were validated against national data. Increasing the levels of prescription of secondary prevention drugs to those patients with CHD might prevent 100 deaths per million population per year and cost an additional £4 million per million population per year. With cost per life year saved of £5520, this appears good value for money compared with other health technologies.

26 March 2018 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
KCKeith Cooper
Keith Cooper
GFGeoff Frampton
Geoff Frampton
PHPetra Harris
Petra Harris
MRMicah Rose
Micah Rose
MCMaria Chorozoglou
Maria Chorozoglou
KPKaren Pickett
Karen Pickett

21 September 2012 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Open access
PDF file
KCKeith Cooper
Keith Cooper
JSJonathan Shepherd
Jonathan Shepherd
JPJo Picot
Jo Picot
JJJeremy Jones
Jeremy Jones
JKJosephine Kavanagh
Josephine Kavanagh
APAlison Price
Alison Price
Objectives: Reducing sexually transmitted infections (STI) and teenage pregnancy through effective health education is a high priority for health policy. Behavioral interventions which teach skills to practice safer sex may reduce the incidence of STIs. We evaluated the cost-effectiveness of school-based behavioral interventions in young people.Methods: We developed an economic model to estimate the total number of STI cases averted, consequent gain in health related quality of life (HRQoL) and savings in medical costs, based on changes in sexual behavior. The parameters for the model were derived from a systematic literature search on the intervention effectiveness, epidemiology of STIs, sexual behavior and lifestyles, HRQoL and health service costs.Results: The costs of providing teacher-led and peer-led behavioral interventions were €5.16 and €18 per pupil, respectively. For a cohort of 1000 boys and 1000 girls aged 15 years, the model estimated that the behavioral interventions would avert two STI cases and save 0.35 Quality Adjusted Life Years (QALYs). Compared to standard education, the incremental cost-effectiveness of the teacher-led and peer-led interventions was €24,268 and €96,938 per QALY gained, respectively.Conclusions: School-based behavioral interventions which provide information and teach young people sexual health skills can bring about improvements in knowledge and increased self-efficacy, though these may be limited in terms of impact on sexual behavior. There was uncertainty around the results due to the limited effect of the intervention on behavioral outcomes and paucity of data for other input parameters.

26 September 2015 in Age and Ageing
Verified
Journal Article
Open access
PDF file
KCKeith Cooper
Keith Cooper
JSJonathan Shepherd
Jonathan Shepherd
GFGeoff Frampton
Geoff Frampton
PHPetra Harris
Petra Harris
ALAndrew J Lotery
Andrew J Lotery
Background: elective cataract surgery is the most commonly performed surgical procedure in developed countries. However, it is unclear whether cataract surgery on the second eye provides enough incremental benefit to be considered cost-effective. This study conducted a cost-effectiveness analysis of second-eye cataract surgery in the UK. Design: a cost-effectiveness analysis. Methods: a decision-analytical model was developed to estimate the cost-effectiveness of second-eye cataract surgery, based on a comprehensive epidemiological and economic review to develop the parameters for the model. The model followed the clinical pathway of cohorts of patients receiving second-eye cataract surgery and included costs and health benefits associated with post-surgical complications. Results: in the model, second-eye surgery generated 0.68 additional quality-adjusted life years (QALY) with an incremental cost-effectiveness ratio of £1,964 per QALY gained. In sensitivity analyses, model results were most sensitive to changes in the health-related quality of life (HRQoL) gain associated with second-eye surgery, but otherwise robust to changes in parameter values. The probability that second-eye surgery is cost-effective at willingness to pay thresholds of £10,000 and £20,000 was 100%. Conclusion: second-eye cataract surgery is generally cost-effective based on the best available data and under most assumptions. However, there are only a small number of clinical trials for second-eye cataract surgery, and these have not been conducted in recent years.